Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- DF2726A, a new IL-8 signalling inhibitor, is able to counteract chemotherapy-induced neuropathic painon August 17, 2019 at 5:34 am
CIPN affects approximately 70% of patients receiving chemotherapeutic treatments, and its development is directly related to the specific drug or combination of anti-cancer agents used, dosing regimen ...
- Then vs. Now: The Cancer-Fighting History of Chemotherapyon August 16, 2019 at 9:20 am
German chemist Paul Ehrlich coined the name “chemotherapy” (“chemo” as in “chemical”) in the early 1900s, but he wasn’t hunting for a cure for cancer. Instead, he was trying to find drugs that could ...
- Three chemotherapy drugs facing shortages across Canadaon August 16, 2019 at 6:27 am
Three chemotherapy drugs that are rated ‘low’ in profitability for pharmaceutical producers are facing shortages across Canada. Vinorelbine, which treats lung and breast cancer, Leucovorin, which ...
- Drug Speeds Renewal of Blood Depleted by Chemo, Radiationon August 16, 2019 at 3:07 am
So, drugs that block the active site of one tyrosine phosphatase ... more than half of those that did not receive the PTPσ inhibitor died within three weeks. In mice that received chemotherapy—at ...
- Targeted pancreatic cancer drug shows promise in clinical trialson August 16, 2019 at 2:30 am
The researchers explained that chemotherapy with Gemcitabine, a standard chemotherapy drug, and radiation therapy used for pancreatic cancer can lead to damage to the DNA. Pancreatic cancer cells can ...
- New drug may speed blood recovery after chemotherapyon August 15, 2019 at 11:23 am
Aug. 15 (UPI) --A new drug may help to speed up the rejuvenation of blood stem cells after chemotherapy, a new study says. Researchers developed a drug that can block a protein known as receptor-type ...
- Drug accelerates blood system's recovery after chemotherapy, radiationon August 15, 2019 at 5:24 am
A drug developed by UCLA physician-scientists and chemists speeds up the regeneration of mouse and human blood stem cells after exposure to radiation. If the results can be replicated in humans ...
- Nanoscale “Glass” Bottles Could Enable Targeted Drug Deliveryon August 14, 2019 at 3:05 pm
In the study, which was published on June 4 in the journal Angewandte Chemie International Edition, the researchers describe packing the spheres with a mixture of fatty acids, a near-infrared dye, and ...
- Global Chemotherapy Drugs Market Estimated to Rising at a Lucrative CAGR of +11.91% between 2019 and 2024on August 14, 2019 at 12:59 pm
Aug 14, 2019 (AmericaNewsHour) -- A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report ...
via Bing News